VSTM
What one share of Verastem holds
Pharmaceutical Preparations
We are a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with challenging RAS/MAPK pathway-driven cancers. We market AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the United States (“U.S.”), the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (“LGSOC”) who have received prior systemic therapy.
Verastem’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.03 |
|---|---|
| Profit | −$2.38 |
| Cash and investments | $1.51 |
| Book value | $0.55 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$0.44 | $0.22 | −$218.74 | — | — |
| 2021 | $0.14 | −$4.90 | $0.01 | −$3.69 | — | — |
| 2022 | $0.16 | −$4.57 | — | −$3.95 | — | $2.84 |
| 2023 | — | −$3.96 | — | −$3.92 | — | $2.27 |
| 2024 | $0.28 | −$3.66 | $0.00 | −$2.93 | — | −$0.65 |
| 2025 | $0.45 | −$3.02 | — | −$1.98 | — | $0.74 |